Insmed met 'much more meaningful' secondary endpoint, says Piper Jaffray Piper Jaffray says Insmed's Phase 2 Study of Arikayce for nontuberculous mycobacteria met the "much more meaningful and clinically relevant" secondary endpoint of culture conversion while missing the less clinically relevant primary endpoint of sputum density. Piper says the drug works and thinks the stock could end up staying close to where it is currently given the split decision on endpoints. The firm reiterates an Overweight rating on Insmed.
Insmed personnel strong, says Piper Jaffray After attending Insmed's analyst event, Piper says that the company has assembled a strong development and commercial team . The firm adds that the company has forged unique relationships with specialists and patients. It keeps an Overweight rating on the shares.